Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams purchased 29,929 shares of the company’s stock in a transaction dated Tuesday, November 17th. The shares were bought at an average price of $1.05 per share, for a total transaction of $31,425.45. Following the completion of the transaction, the director directly owned 36,992,865 shares in the company, valued at approximately $38,842,508.25. This trade represents a 0.08% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Gregg Williams also recently made the following trade(s):
- On Monday, November 16th, Gregg Williams bought 2,100 shares of Vivani Medical stock. The stock was bought at an average cost of $1.01 per share, for a total transaction of $2,121.00.
- On Friday, November 13th, Gregg Williams bought 48,100 shares of Vivani Medical stock. The shares were purchased at an average cost of $0.99 per share, with a total value of $47,619.00.
Vivani Medical Price Performance
Shares of VANI remained flat at $1.05 during mid-day trading on Wednesday. The stock had a trading volume of 177,181 shares, compared to its average volume of 323,023. The firm’s 50 day simple moving average is $1.17 and its 200-day simple moving average is $1.24. The company has a market cap of $94.71 million, a PE ratio of -3.28 and a beta of 2.51. Vivani Medical, Inc. has a 52 week low of $0.80 and a 52 week high of $1.66.
Vivani Medical (NASDAQ:VANI – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01.
Analyst Ratings Changes
A number of analysts have commented on the stock. Wall Street Zen downgraded shares of Vivani Medical from a “hold” rating to a “sell” rating in a research report on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vivani Medical in a research report on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.75.
View Our Latest Analysis on VANI
Vivani Medical Company Profile
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
See Also
- Five stocks we like better than Vivani Medical
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
